What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis

Yvonne L. Luigjes-Huizer; Nina M. Tauber; Gerry Humphris; Nadine A. Kasparian; Wendy W. T. Lam; Sophie Lebel; Sébastien Simard; Allan Ben Smith; Robert Zachariae; Yati Afiyanti; Katy J. L. Bell; José A. E. Custers; Niek J. de Wit; Peter L. Fisher; Jacqueline Galica; Sheila N. Garland; Charles W. Helsper; Mette M. Jeppesen; Jianlin Liu; Roxana Mititelu; Evelyn M. Monninkhof; Lahiru Russell; Josée Savard; Anne E. M. Speckens; Sanne J. van Helmondt; Sina Vatandoust; Nicholas Zdenkowski; Marije L. van der Lee

doi:10.1002/pon.5921

What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis

Yvonne L. Luigjes-Huizer, Nina M. Tauber, Gerry Humphris, Nadine A. Kasparian, Wendy W. T. Lam, Sophie Lebel, Sébastien Simard, Allan Ben Smith, Robert Zachariae, Yati Afiyanti, Katy J. L. Bell, José A. E. Custers, Niek J. de Wit, Peter L. Fisher, Jacqueline Galica, Sheila N. Garland, Charles W. Helsper, Mette M. Jeppesen, Jianlin Liu, Roxana MititeluEvelyn M. Monninkhof, Lahiru Russell, Josée Savard, Anne E. M. Speckens, Sanne J. van Helmondt, Sina Vatandoust, Nicholas Zdenkowski, Marije L. van der Lee

School of Medicine

Research output: Contribution to journal › Review article › peer-review

115 Citations (Scopus)

17 Downloads (Pure)

Abstract

Objective

Care for fear of cancer recurrence (FCR) is considered the most common unmet need among cancer survivors. Yet the prevalence of FCR and predisposing factors remain inconclusive. To support targeted care, we provide a comprehensive overview of the prevalence and severity of FCR among cancer survivors and patients, as measured using the short form of the validated Fear of Cancer Recurrence Inventory (FCRI-SF). We also report on associations between FCR and clinical and demographic characteristics.

Methods

This is a systematic review and individual participant data (IPD) meta-analysis on the prevalence of FCR. In the review, we included all studies that used the FCRI-SF with adult (≥18 years) cancer survivors and patients. Date of search: 7 February 2020. Risk of bias was assessed using the Joanna Briggs Institute critical appraisal tool.

Results

IPD were requested from 87 unique studies and provided for 46 studies comprising 11,226 participants from 13 countries. 9311 respondents were included for the main analyses. On the FCRI-SF (range 0–36), 58.8% of respondents scored ≥13, 45.1% scored ≥16 and 19.2% scored ≥22. FCR decreased with age and women reported more FCR than men. FCR was found across cancer types and continents and for all time periods since cancer diagnosis.

Conclusions

FCR affects a considerable number of cancer survivors and patients. It is therefore important that healthcare providers discuss this issue with their patients and provide treatment when needed. Further research is needed to investigate how best to prevent and treat FCR and to identify other factors associated with FCR.

The protocol was prospectively registered (PROSPERO CRD42020142185).

Original language	English
Journal	Psycho-Oncology
Volume	Early View
Early online date	7 Apr 2022
DOIs	https://doi.org/10.1002/pon.5921
Publication status	E-pub ahead of print - 7 Apr 2022

Keywords

Cancer
Correlates
Fear of recurrence
Oncology
Prevalence

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/pon.5921Licence: CC BY-NC-ND

Luigjes‐Huizer_2022_Psych-Oncology_Fear_CC
Copyright © 2022 The Authors. Psycho-Oncology published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Final published version, 623 KBLicence: CC BY-NC-ND

Cite this

Luigjes-Huizer, Y. L., Tauber, N. M., Humphris, G., Kasparian, N. A., Lam, W. W. T., Lebel, S., Simard, S., Smith, A. B., Zachariae, R., Afiyanti, Y., Bell, K. J. L., Custers, J. A. E., de Wit, N. J., Fisher, P. L., Galica, J., Garland, S. N., Helsper, C. W., Jeppesen, M. M., Liu, J., ... van der Lee, M. L. (2022). What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis. Psycho-Oncology, Early View. Advance online publication. https://doi.org/10.1002/pon.5921

@article{583cc6cb2b2b4fea9d74307c2341574d,

title = "What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis",

abstract = " Objective Care for fear of cancer recurrence (FCR) is considered the most common unmet need among cancer survivors. Yet the prevalence of FCR and predisposing factors remain inconclusive. To support targeted care, we provide a comprehensive overview of the prevalence and severity of FCR among cancer survivors and patients, as measured using the short form of the validated Fear of Cancer Recurrence Inventory (FCRI-SF). We also report on associations between FCR and clinical and demographic characteristics. Methods This is a systematic review and individual participant data (IPD) meta-analysis on the prevalence of FCR. In the review, we included all studies that used the FCRI-SF with adult (≥18 years) cancer survivors and patients. Date of search: 7 February 2020. Risk of bias was assessed using the Joanna Briggs Institute critical appraisal tool. Results IPD were requested from 87 unique studies and provided for 46 studies comprising 11,226 participants from 13 countries. 9311 respondents were included for the main analyses. On the FCRI-SF (range 0–36), 58.8% of respondents scored ≥13, 45.1% scored ≥16 and 19.2% scored ≥22. FCR decreased with age and women reported more FCR than men. FCR was found across cancer types and continents and for all time periods since cancer diagnosis. Conclusions FCR affects a considerable number of cancer survivors and patients. It is therefore important that healthcare providers discuss this issue with their patients and provide treatment when needed. Further research is needed to investigate how best to prevent and treat FCR and to identify other factors associated with FCR. The protocol was prospectively registered (PROSPERO CRD42020142185). ",

keywords = "Cancer, Correlates, Fear of recurrence, Oncology, Prevalence",

author = "Luigjes-Huizer, {Yvonne L.} and Tauber, {Nina M.} and Gerry Humphris and Kasparian, {Nadine A.} and Lam, {Wendy W. T.} and Sophie Lebel and S{\'e}bastien Simard and Smith, {Allan Ben} and Robert Zachariae and Yati Afiyanti and Bell, {Katy J. L.} and Custers, {Jos{\'e} A. E.} and {de Wit}, {Niek J.} and Fisher, {Peter L.} and Jacqueline Galica and Garland, {Sheila N.} and Helsper, {Charles W.} and Jeppesen, {Mette M.} and Jianlin Liu and Roxana Mititelu and Monninkhof, {Evelyn M.} and Lahiru Russell and Jos{\'e}e Savard and Speckens, {Anne E. M.} and {van Helmondt}, {Sanne J.} and Sina Vatandoust and Nicholas Zdenkowski and {van der Lee}, {Marije L.}",

note = "This study was supported by the Dutch Cancer Society (KWF) grant number 10936. ",

year = "2022",

month = apr,

day = "7",

doi = "10.1002/pon.5921",

language = "English",

volume = "Early View",

journal = "Psycho-Oncology",

issn = "1057-9249",

publisher = "Wiley",

}

Luigjes-Huizer, YL, Tauber, NM, Humphris, G, Kasparian, NA, Lam, WWT, Lebel, S, Simard, S, Smith, AB, Zachariae, R, Afiyanti, Y, Bell, KJL, Custers, JAE, de Wit, NJ, Fisher, PL, Galica, J, Garland, SN, Helsper, CW, Jeppesen, MM, Liu, J, Mititelu, R, Monninkhof, EM, Russell, L, Savard, J, Speckens, AEM, van Helmondt, SJ, Vatandoust, S, Zdenkowski, N & van der Lee, ML 2022, 'What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis', Psycho-Oncology, vol. Early View. https://doi.org/10.1002/pon.5921

TY - JOUR

T1 - What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis

AU - Luigjes-Huizer, Yvonne L.

AU - Tauber, Nina M.

AU - Humphris, Gerry

AU - Kasparian, Nadine A.

AU - Lam, Wendy W. T.

AU - Lebel, Sophie

AU - Simard, Sébastien

AU - Smith, Allan Ben

AU - Zachariae, Robert

AU - Afiyanti, Yati

AU - Bell, Katy J. L.

AU - Custers, José A. E.

AU - de Wit, Niek J.

AU - Fisher, Peter L.

AU - Galica, Jacqueline

AU - Garland, Sheila N.

AU - Helsper, Charles W.

AU - Jeppesen, Mette M.

AU - Liu, Jianlin

AU - Mititelu, Roxana

AU - Monninkhof, Evelyn M.

AU - Russell, Lahiru

AU - Savard, Josée

AU - Speckens, Anne E. M.

AU - van Helmondt, Sanne J.

AU - Vatandoust, Sina

AU - Zdenkowski, Nicholas

AU - van der Lee, Marije L.

N1 - This study was supported by the Dutch Cancer Society (KWF) grant number 10936.

PY - 2022/4/7

Y1 - 2022/4/7

N2 - Objective Care for fear of cancer recurrence (FCR) is considered the most common unmet need among cancer survivors. Yet the prevalence of FCR and predisposing factors remain inconclusive. To support targeted care, we provide a comprehensive overview of the prevalence and severity of FCR among cancer survivors and patients, as measured using the short form of the validated Fear of Cancer Recurrence Inventory (FCRI-SF). We also report on associations between FCR and clinical and demographic characteristics. Methods This is a systematic review and individual participant data (IPD) meta-analysis on the prevalence of FCR. In the review, we included all studies that used the FCRI-SF with adult (≥18 years) cancer survivors and patients. Date of search: 7 February 2020. Risk of bias was assessed using the Joanna Briggs Institute critical appraisal tool. Results IPD were requested from 87 unique studies and provided for 46 studies comprising 11,226 participants from 13 countries. 9311 respondents were included for the main analyses. On the FCRI-SF (range 0–36), 58.8% of respondents scored ≥13, 45.1% scored ≥16 and 19.2% scored ≥22. FCR decreased with age and women reported more FCR than men. FCR was found across cancer types and continents and for all time periods since cancer diagnosis. Conclusions FCR affects a considerable number of cancer survivors and patients. It is therefore important that healthcare providers discuss this issue with their patients and provide treatment when needed. Further research is needed to investigate how best to prevent and treat FCR and to identify other factors associated with FCR. The protocol was prospectively registered (PROSPERO CRD42020142185).

AB - Objective Care for fear of cancer recurrence (FCR) is considered the most common unmet need among cancer survivors. Yet the prevalence of FCR and predisposing factors remain inconclusive. To support targeted care, we provide a comprehensive overview of the prevalence and severity of FCR among cancer survivors and patients, as measured using the short form of the validated Fear of Cancer Recurrence Inventory (FCRI-SF). We also report on associations between FCR and clinical and demographic characteristics. Methods This is a systematic review and individual participant data (IPD) meta-analysis on the prevalence of FCR. In the review, we included all studies that used the FCRI-SF with adult (≥18 years) cancer survivors and patients. Date of search: 7 February 2020. Risk of bias was assessed using the Joanna Briggs Institute critical appraisal tool. Results IPD were requested from 87 unique studies and provided for 46 studies comprising 11,226 participants from 13 countries. 9311 respondents were included for the main analyses. On the FCRI-SF (range 0–36), 58.8% of respondents scored ≥13, 45.1% scored ≥16 and 19.2% scored ≥22. FCR decreased with age and women reported more FCR than men. FCR was found across cancer types and continents and for all time periods since cancer diagnosis. Conclusions FCR affects a considerable number of cancer survivors and patients. It is therefore important that healthcare providers discuss this issue with their patients and provide treatment when needed. Further research is needed to investigate how best to prevent and treat FCR and to identify other factors associated with FCR. The protocol was prospectively registered (PROSPERO CRD42020142185).

KW - Cancer

KW - Correlates

KW - Fear of recurrence

KW - Oncology

KW - Prevalence

U2 - 10.1002/pon.5921

DO - 10.1002/pon.5921

M3 - Review article

SN - 1057-9249

VL - Early View

JO - Psycho-Oncology

JF - Psycho-Oncology

ER -

What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this